SPY AGENT GREEN LYMPHATICS KIT FOR ADVANCED IMAGING MODALITY (AIM) AND PINPOINT

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Preuzimanje Svojstava lijeka (SPC)
28-11-2018

Aktivni sastojci:

INDOCYANINE GREEN

Dostupno od:

NOVADAQ TECHNOLOGIES ULC

ATC koda:

V04CX01

INN (International ime):

INDOCYANINE GREEN

Doziranje:

25MG

Farmaceutski oblik:

KIT

Sastav:

INDOCYANINE GREEN 25MG

Administracija rute:

INTERSTITIAL

Jedinice u paketu:

15G/50G

Tip recepta:

Ethical

Područje terapije:

ROENTGENOGRAPHY

Proizvod sažetak:

Active ingredient group (AIG) number: 0150962001; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2020-05-01

Svojstava lijeka

                                SPY AGENT™ GREEN
Indocyanine Green for Injection, USP
25 mg/vial
Lyophilized powder for intravenous or interstitial injection
Fluorescent Imaging Agent
Novadaq Technologies ULC. (now a part of Stryker)
8329 Eastlake Drive, Unit 101
Burnaby, British Columbia
V5A 4W2
Date of Draft:
November 28, 2018
Date of Initial Approval:
Date of Revision:
Submission Control No: 213662
Page 2 of 20
TABLE OF CONTENTS
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................4
1
INDICATIONS
..................................................................................................................4
1.1
Pediatrics
...............................................................................................................4
1.2
Geriatrics
...............................................................................................................4
2
CONTRAINDICATIONS
.................................................................................................4
3
DOSAGE AND ADMINISTRATION
.............................................................................5
3.1
Dosing Considerations
..........................................................................................5
3.2
Recommended Dose and Dosage Adjustment
......................................................5
3.3
Administration
......................................................................................................5
3.4
Reconstitution
.......................................................................................................6
3.5
Missed Dose
..........................................................................................................7
4
OVERDOSAGE
.................................................................................................................7
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................8
6
WARNINGS AN
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 28-11-2018

Upozorenja za pretraživanje vezana za ovaj proizvod